Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: An exploratory analysis

Retina

Volumn 25, Issue 7, 2005, Pages 815-827

  Gonzales, Christine R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; Aptamer; Choroidal neovascularization; Early disease; Macular degeneration; Pegaptanib; Randomized clinical trial; Vascular endothelial growth factor (VEGF)

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; PEGAPTANIB; PLACEBO; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EARLY DIAGNOSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHOTODYNAMIC THERAPY; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA AGE RELATED DEGENERATION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VALIDATION PROCESS; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; APTAMERS, NUCLEOTIDE; CHOROIDAL NEOVASCULARIZATION; DOUBLE-BLIND METHOD; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; MACULAR DEGENERATION; MALE; MIDDLE AGED; OLIGONUCLEOTIDES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 26844508345     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006982-200510000-00001     Document Type: Article

References (42)

1. Klein R, Wang Q, Klein BE, et al. The relationship of age-related maculopathy, cataract, and glaucoma to visual acuity. Invest Ophthalmol Vis Sci 1995;36:182-191.
2. Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. Surv Ophthalmol 1988;32:375-413.
3. Leibowitz HM, Krueger DE, Maunder LR, et al. The Framingham Eye Study monograph: an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults: 1973-1975. Surv Ophthalmol 1980;24:S335-S610.
4. Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984;102:1640-1642.
5. Macular Photocoagulation Study Group. Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration. The influence of initial lesion size and initial visual acuity. Arch Ophthalmol 1994;112:480-488.
6. Ciulla TA, Danis RP, Harris A. Age-related macular degeneration: a review of experimental treatments. Surv Ophthalmol 1998;43:134-146.
7. Bressler NM, Maguire MG, Murphy PL, et al. Macular scatter ('grid') laser treatment of poorly demarcated subfoveal choroidal neovascularization in age-related macular degeneration. Results of a randomized pilot trial. Arch Ophthalmol 1996;114:1456-1464.
8. Visudyne [package insert]. Duluth, GA: Novartis Ophthalmics, Inc.; 2003.
9. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. One-year results of 2 randomized clinical trials-TAP report 1. Arch Ophthalmol 1999;117:1329-1345.
10. Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. One-year results of a randomized clinical trial-VIP report no. 1. Ophthalmology 2001;108:841-852.
11. Adamis AP, Miller JW, Bernal M-T, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994;118:445-450.
12. Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 1996;114:66-71.
13. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-1487.
14. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995;92:10457-10461.
15. Amano S, Rohan R, Kuroki M, et al. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 1998;39:18-22.
16. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002;120:338-346.
17. Leung DW, Cachianes G, Kuang W-J, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-1309.
18. Malecaze F, Clamens S, Simorre-Pinatel V, et al. Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol 1994;112:1476-1482.
19. Tolentino MJ, McLeod DS, Taomoto M, et al. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol 2002;133:373-385.
20. Tolentino MJ, Miller JW, Gragoudas ES, et al. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol 1996;114:964-970.
21. Schwesinger C, Yee C, Rohan RM, et al. Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium. Am J Pathol 2001;158:1161-1172.
22. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816.
23. Macugen [package insert]. New York, NY: Eyetech Pharmaceuticals and Pfizer Inc.; 2004.
24. Gregor Z, Bird AC, Chisholm H. Senile disciform macular degeneration in the second eye. Br J Ophthalmol 1977;61:141-147.
25. Grossniklaus HE, Gass JD. Clinicopathologic correlations of surgically excised type 1 and type 2 submacular choroidal neovascular membranes. Am J Ophthalmol 1998;126:59-69.
26. Lafaut BA, Aisenbrey S, Vanden Broecke C, et al. Clinicopathological correlation in exudative age related macular degeneration: histological differentiation between classic and occult choroidal neovascularisation. Br J Ophthalmol 2000;84:239-243.
27. Sarks JP, Sarks SH, Killingsworth MC. Morphology of early choroidal neovascularisation in age-related macular degeneration: correlation with activity. Eye 1997;11(Pt 4):515-522.
28. Killingsworth MC. Angiogenesis in early choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 1995;233:313-323.
29. Gass JDM. Diseases causing choroidal exudative and hemorrhagic localized (disciform) detachment of the retina and retinal pigment epithelium. In: Gass JDM, ed. Stereoscopic Atlas of Macular Diseases. 4th ed. Vol 1. St. Louis: Mosby; 1997.
30. Bressler NM. Early detection and treatment of neovascular age-related macular degeneration. J Am Board Fam Pract 2002;15:142-152.
31. Bressler SB, Bressler NM, Fine SL, et al. Natural course of choroidal neovascular membranes within the foveal avascular zone in senile macular degeneration. Am J Ophthalmol 1982;93:157-163.
32. Vander JF, Morgan CM, Schatz H. Growth rate of subretinal neovascularization in age-related macular degeneration. Ophthalmology 1989;96:1422-1426.
33. Bressler NM, Frost LA, Bressler SB, et al. Natural course of poorly defined choroidal neovascularization associated with macular degeneration. Arch Ophthalmol 1988;106:1537-1542.
34. Macular Photocoagulation Study Group. Occult choroidal neovascularization. Influence on visual outcome in patients with age-related macular degeneration. Arch Ophthalmol 1996;114:400-412.
35. Lozano-Rechy D, Duker JS, Jalkh AE. Lipid exudation in age-related macular degeneration. Am J Ophthalmol 1993;116:140-147.
36. Lowenstein A, Bressler NM. Neovascular (exudative) age-related macular degeneration. In: Guyer DR, Yannuzzi LA, Chang S, et al, eds. Retina-Vitreous-Macula. Vol 1. Philadelphia: WB Saunders; 1999.
37. Roy M, Daiser Kupfer M. Second eye involvement in age-related macular degeneration. A four-year prospective study. Eye 1990;4:813-818.
38. Pieramici DJ, Bressler SB. Age-related macular degeneration and risk factors for the development of choroidal neovascularisation in the fellow eye. Curr Opin Ophthalmol 1998;9:38-46.
39. Macular Photocoagulation Study Group. A five-year follow-up of fellow eyes of patients with age-related macular degeneration. Arch Ophthalmol 1993;111:1189-1199.
40. Macular Photocoagulation Study Group. Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Arch Ophthalmol 1977;115:741-747.
41. Green WR. Histopathology of age-related macular degeneration. Mol Vis 1999;5:27.
42. ICH Expert Working Group. ICH harmonized tripartite guidelines: statistical principles for clinical trials E9. Available at: ICH.org. Accessed March 29, 2005.